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Abstract 
  
As aculturization and globalization continues, there is an urgent need to carefully record and delineate 
traditional pharmacopeias so that their true worth is understood and protected and any possible benefits related to 
their commercial development are equitably distributed.  In the past most of these endeavors resulted in a list of 
plants with their associated uses without providing further explanations as to the extent of this knowledge within the 
traditional group, or if this knowledge was known elsewhere.  This practice tended to generate the notion of finite 
exclusivity without providing proof that this was actually the case.  Moreover, since the talents and methods of those 
conducting these initial studies varied widely, little effort was made to provide adequate information on how selective 
processes and preferences as well as modes of collection, preparation and use were achieved.  Without these data, 
the potential of their clinical worth, bioreactive capacities or chemical compositions were often compromised.  This 
frequently led to expending much time, effort and treasure on a pharmacopeia’s evaluation without guidance on how 
these efforts could be optimized to achieve its best possible medicinal potential. This paper will review how types of 
dereplications and other techniques are helpful in amplifying this process. 
 
 
 
Introduction 
 
 Before appropriate dereplications can be applied to a traditional pharmacopeia it is important to know how 
these data were acquired and by whom.  The worth of this information is dependant upon the expertise of not only 
those involved in the acquisition of the data but also those that examine its worth. Nowadays to corroborate and/or 
exploit the medicinal value of a traditional-based pharmacopeia it is important to utilize the talents of many expert 
scientists. Such endeavors should be viewed as a team effort, with data evolved by one type of investigator providing 
insights to others along the validation process. 
 In the past it was not unusual for medicinal plant inventories pertaining to a specific traditional pharmacopeia 
to be conducted by individuals who were limited in their expertise.  This often generated a list of plants and/or local 
names associated with some, but not necessarily all of their uses.  I have observed that depending on the extent of 
the study, this occasionally results in incomplete or erroneous information being recorded regarding the true nature of 
the malady or remedy or the correct identification of the plant itself.  In the latter instance, when accompanying plant 
vouchers were not provided, or inappropriately prepared without fruit and/or flowers, misidentifications could be made 
in a variety of ways. Sometimes this has meant depending on local names to guide determinations without 
understanding if one or more disparate taxa were associated with this epithet e.g., Akan designation of “tweapea” for 
Garcinia afzellii and G. epunctata  (Adu-tutu. et al 1979; Elvin-Lewis, 1980, Elvin-Lewis, 1982).   There was also a 
tendency to list plants for a use without citing when and how the plant was collected, what plant part might be used, 
how it might be stored and prepared, and if it was used alone, sequentially or in combination with other plants or other 
substances.  
 Also, without knowledge of the local language or medical terms that were locally applied or conventionally 
known, medical descriptors could be so vague as to refer to the incorrect disease syndrome, or eliminate particular 
details, which could have further aided in the diagnosis.  This is particularly true in cases of those with multiple 
etiologies.  For example, detailed descriptions of symptoms are frequently critical to an appropriate diagnosis and/or 
etiological identification of gastrointestinal, dermatological or pulmonary infections.  Thus, in one ethnopharmacology 
Amazonian study related to traditional treatments for viral diarrheas among the Kayapó of Brazil, information 
regarding the duration of the illness and the nature of the stools was considered trivial and not recorded.  These 
omissions were unfortunate since it is generally recognized in the medical community that a short acute illness is 
more likely to be viral in origin and the color and consistency of fecal excrement is often indicative of the cause of the 
problem at least at the level of whether or not it is bacterial or parasitic in nature. Appreciating these differences would 
have been useful in prioritizing the evaluations that were executed.  In spite of this exclusion, the authors did conduct 
sufficient chemical and ethnobotanical dereplications so they were able to determine that “most of the genera 
employed included species that contained classes of compounds relevant to antiviral activity, or are related to species  
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used by other peoples for viral diseases or gastrointestinal troubles” (Elisabethsky and Posey, 1994). Causes of 
pulmonary infections are particularly difficult to assess unless one understands the types of disease that are regionally 
recognized, if they are acute or chronic, seasonal or perennial, primarily affect one age group or another, or if any 
unique symptoms (nature of sputa, cough etc) are related to a certain condition.  Adding this type of information is 
particularly valuable when additional in vitro studies are used to evaluate their worth such as for certain bacterial 
infections like tuberculosis, viral infections like influenza, or parasitic infestations, which cause lung involvement.  
 Understanding the nature and epidemiology of diseases, which are prominent in the study area is useful in 
distinguishing what might be expected and what might be unusual.  This is true for numerous infectious diseases as it 
is or certain medical ailments with circumscribed regional distributions. For example, confusion of what is meant by a 
medical descriptor may relate to how it is interpreted by the translator or in translation from one language to another.  
For instance, an ethnomedical study in Polynesia described the treatment of “yellow fever” by Homalanthus nutans 
(Euphorbiaceae) (Cox, 1991).  Since this virus was unknown to the locality I questioned those familiar with the 
Samoan language and the study and asked them how the ailment had been described.  Apparently the descriptor 
meant “yellowing eyes” inferring that the patient had jaundice, possibly due to hepatitis B (HBV) which is endemic to 
the region. These made sense since additional studies indicated its prostratin was inhibitory against Human 
Immunodeficiency viruses (HIV) and these viruses and HBV both possess reverse transcriptases (RT) (Lewis and 
Elvin-Lewis, 2003).  Of note, many plant compounds can elicit this interesting cross sensitivity.  Also, during the time I 
was involved in conducting a medicinal plant inventory of an indigenous Amazonian tribe our translator referred to a 
skin rash as being small pox.  As an infectious disease microbiologist this did not seem logical to me since there was 
a lack of variola-scarring in the populace.  In questioning the informant regarding the symptoms being reported it was 
apparent that the individual was referring to measles (rubeola) that was known to occur in the region. 
 To treat certain diseases several disparate groups have utilized the “doctrine of signatures” to select certain 
of their medicinal plants according to their shape or color etc., with the notion that these indicators provide some sort  
of cosmic clue as to their usefulness.  While many of these signs have little value, one cannot totally disregard all of 
these interesting secondary selective criteria.  Perhaps the best example is its application in identifying plant parts 
useful in the treatment of hepatitis and jaundice.  For example, in studying Amazonian hepatitis remedies a significant 
number of those selected fell into this category (Elvin-Lewis et al., 2002). In these cases as well as in other 
pharmacopeias I have examined worldwide, identifiable efficacious yellow compounds such as antioxidant and 
antiviral flavonoids have often been associated with the yellow fruits, roots, flowers and/or barks found in these 
formulations. Another example related to leaf shape was the use of the Penobscot Amerindians of Mayapple 
(Podophyllum spp) to treat venereal warts (Condyloma acuminata). This plant has serrated and multi-lobed leaves, 
which are similar in shape to these anal lesions. In the latter instance, this led to the identification of its bioreactive 
podophyllotoxins and the semi-synthesis of the topisomerase inhibitors, teniposide and etoposide useful in the 
treatment of cancers such as leukemia, lymphomas, as well as brain and bladder cancers (Lewis and Elvin-Lewis, 
2003). 
 The quality of data that is acquired during the initial interviewing process is but one aspect to be considered.  
Pivotal to the process of understanding a traditional-based pharmacopeia is to determine the type of medicinal 
practices that are involved, and if the knowledge is widespread and practiced among members of a community or only 
known to circumscribed healers. These differences will depend upon the number of individuals that should be 
interviewed within a neighborhood or regionally so a realistic consensus of what is valued and by whom can be 
generated.  Within this context one must be mindful of the fact that there are numerous selective processes at play as 
to how these remedies are chosen including a variety of social parameters together with those preferences based on 
gender, tribe or religion.  The contents of these remedies and prescribed uses may be rigidly adhered to or vary even 
within family units. However, when significant data are garnered from both practitioners and/or users alike, these 
perceptions of value can be applied to affirm their merit.  This is particularly true when a large number of specific 
treatments are known for a specific condition and when there is a critical need to identify those of value to the health 
of a community or region.  Detailed studies associated with chewing-stick use in Ghana (Adu-tutu et al., 1979, Elvin-
Lewis et al., 1980) and Amazonian hepatitis remedies in Peru (Elvin-Lewis et al., 2002), called “ethnomedical 
focusing” provided insights into the worth of this type of effort. In both instances, favored species proved to have 
significant relevant bioreactivities when laboratory studies were conducted, clinical verifications made, and 
appropriate ethnobotanical and/or chemical dereplications were executed.  
 Access to secondary information was limited in the past since academic libraries and the like rarely had 
sufficient collections of published data, access to government reports, theses from other nearby institutions etc. to 
provide investigators with information about related and/or regional pharmacopeias.  Also, when published in local 
languages, these were limited to those with the necessary linguistic expertise. The process of retrieving prior 
information from written reports could be painstaking whenever these sources failed to have adequate indices to 
facilitate the process.  Similarly, only large herbaria were likely to have large enough collections to provide a 
comprehensive overview of the distribution of the taxa, or have specimens with labels indicating ethnomedical uses. 
Presently, because of the need to protect traditional knowledge as “know how”, it is likely that some recent collections 
will indicate that ethnomedical data has been redacted from the herbarium label but is available through access to a 
defensive database (Elvin-Lewis, 2006; Elvin-Lewis 2007a; Elvin-Lewis 2007b; Christian, 2009).    
 
doi: 10.4314/ajtcam.v8i5S.12
Elvin-Lewis  Afr J Tradit Complement Altern Med. (2011) 8(S):13-26 
 
15
 Today, many of these past problems have been overcome through information being readily retrieved from a 
wide range of electronically-based databases in ethnobotany, botany, biomedicine, pharmacognosy, chemistry, and 
clinical medicine including the process of meta-analytical and relevant patent pending or patented items from national 
and global patent agencies.  Aside from these specialized and professional resources, the internet is replete with 
additional information (accurate or otherwise) on subjects pertaining to medicinal plants and their uses.  These 
dereplication processes are invaluable in revealing what is already known, and how studies should proceed to 
optimize the worth of a traditional pharmacopeia as well as being helpful in revealing new avenues for research that 
might not otherwise be apparent.    
 
Ethical Considerations 
 
The issue of protecting traditional knowledge is an ongoing process as is evident by the ongoing draft 
revision of the WHO 1993 guidelines related to the conservation of medicinal plants, national and regional 
conferences on the subject, in addition to recent reports (Christian, 2009). Since the object of this paper is to provide 
ways in which pharmacopeias can be validated for their worth and/or commercial potential it is important that all future 
studies comply with these ethical guidelines and are sensitive to global, regional and national policies and laws which 
would impact on such endeavors.  Readers may also refer to discussions on how both collective (CK) and traditional 
knowledge (TK) are defined, how claims of ownership can vary and can be utilized if in the public domain, in addition 
to ways circumscribed TK might be protected through defensive databases, trade secrets, sui generis laws, and the 
“requirement” associated with TK-associated genetic resources (Elvin-Lewis 2006, Elvin-Lewis 2007a, 2007b). 
 
Ethnobotanical/Ethnomedical Dereplication  
 
 The challenges to utilizing a unified approach when addressing the complexities of ethnobotanical research 
and applying bioinformatics are continuing and have yet to be resolved.  However practical solutions are likely to 
emerge as information technologies evolve and become more user friendly (Thomas, 2003). 
Until a consensus evolves these tasks may be pain-staking because of the lack of standardization and the myriad of 
ways this information is available.  Nonetheless these efforts are worthwhile if the full value of a traditional 
pharmacopeia is to be realized. 
  Ethnobotanical/ Ethnomedical dereplications are useful in determining the derivation of a remedy, whether 
or not it is ethnically specific, if it has been introduced from elsewhere through migration of populations or otherwise, if 
the use of the remedy is widespread because of its popularity or the distribution of the species, if it is used alone or as 
a mixture, and if treatment criteria gives a clue as to its value.  This technique is also useful in identifying related 
species, when sourcing issues demand alternate supplies. An understanding how this might be achieved has already 
been addressed in detail (Elvin-Lewis 2005a, Elvin-Lewis, 2005b, Elvin-Lewis, 2010). To emphasize the value of this 
and related methodologies a number of aspects will be reiterated throughout this paper.  
 Applying this knowledge is essential to identifying those remedies worthy of additional study.  For example, 
in today’s evolving paradigm it is becoming evident that medicinal plants, already preselected by empirical methods, 
are more likely to elicit positive “hits” when screened for a particular bioreactivity than those studied from plant 
libraries representing random collections of local or regional floras.  This is particularly true if the assay methods are 
complementary to mechanisms associated with “targeted” diseases. 
 However, this was not always the case.  Up until the late 20th century both the U.S. National Cancer Institute 
(NCI) and Industry believed that mass screening of randomly collected plants was more likely to yield unique and 
interesting compounds, than when their ethnomedical uses were taken into consideration. Using this approach a small 
number (2-8%) of active compounds was isolated from 32,000 species of flowering plants screened worldwide 
between 1956-81(WHO, 1989). A shining example of this effort was the discovery of the complex anticancer 
molecule, paclitaxel (taxol) from the North American Yew, Taxus brevifolia .  However, retrospective ethnomedical 
dereplication conducted several years later indicated that indeed an ethnomedical linkage existed in that the First 
Nation Tsimshian of Northern British Columbia and Alaska had used T. brevifolia ‘s wood for the treatment of cancers 
(Moerman 1991).  Moreover, when alternative sources were needed to satisfy the growing need for paclitaxel, an 
examination of other species for this compound or precursor molecules was initiated. Among these was the 
Himalayan anticancer plant T. walachiana, cited in the Bower Manuscript written between 1893 and 1912.  It is 
noteworthy that in the early days of paclitaxel’s development this association was known to NCI but not considered 
relevant (Hartwell, 1967).  It was only when this species and the European yew, T. baccata was identified as the 
potential source of the precursor molecule, baccatin III, needed to produce the semi-synthetic analog docetaxel, that a 
better appreciation of the worth of ethnomedical knowledge began to evolve. (Lewis and Elvin-Lewis, 2003). 
 At this time a number of other studies were beginning to indicate that screening of medicinal plants, which 
had been essentially disbanded, was once again becoming a worthwhile endeavor. This was particularly true when 
collaborative efforts evolved between those still utilizing their pharmacopeias and expert scientists that were able to 
accurately evaluate their worth. Optimal correlative results clearly depended upon the specificity of the assays and 
clinical evaluations that were being applied.   
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Other comprehensive databases of specific regions, countries or populations may represent general compellations of 
an individual, specific group or organization.  Their usefulness is variable because of the quality and quantity of data 
presented.  Utilization of these may be free or require a fee or membership to an organization. 
  Regionally based databases include those assembled from the traditional medicinal systems of Asia as 
generated by World Intellectual Property Organization (WIPO) member states of China, India and Korea. PROSEA 
(Plant Resources of South-East Asia) is a collaborative effort of participating organizations in Indonesia, Malaysia, 
Papua New Guinea, Phillipines, Thailand, VietNam with publishing offices in Wageningen, Netherlands). For Africa, 
Prelude Medicinal Base of African ethnobotany and ethnomedicine encompasses information used by humans and for 
veterinarian purposes gleaned from the colonial period until today. These data are correlated with current information 
related to taxonomic and biomedical research. PROTA, available in either English or French is another database, 
which identifies useful plants of tropical Africa. Medicinal plants of the Caribbean and Latin America can be found in 
TRAMIL which has generated an ebook on the Caribbean pharmacopeia in addition to a CD-ROM on conservation.  
Some databases attributed to uses in the Peruvian Amazon, the greater southwest and South Florida of the U.S. may 
be limited in scope. 
 Those of national origin include Bangladesh, Brazil, Brunei, China (Chinese Medicinal Material Research 
Center (CMMRC), India (MEDFLOR, NATTS, INMEDPLAN,AYUSH,TKDL), Hawaii, Indonesia, Papua New Guinea, 
Madagascar, Malta, Samoa, Russia (Florin Medicinal Plants), Spain, Thailand, Tibet and Turkey (FLOTURK).   
 Additional sources may be restricted to circumscribed groups such as the Gwich’in of Northern Canada, the 
Aboriginal people of Australia, Maya of Central America, the Quijos of the Andes, or those in India that practice 
specialized medicinal systems such as Aryurveda (Unnikrishnan, 2005) or AYUSH (Aryurveda, Yoga, Unani, 
Naturopathy, Siddha and Homeopathy).  Alternately, the Native American Ethnobotany Database describes uses of 
indigenous Amerindian tribes/1st Nations in both the U.S. and Canada, respectively. 
 Noteworthy among the free databases generated by the U.S. government is one for agriculture called 
ARICOLA with over 3 million records of post 1970 publications and those found in the Phytochemical and 
Ethnobotanical databases compiled by J. Duke. Others related to medicinal plants such as The International 
Bibliographic Information on Dietary Supplements (IBIDS) (a PubMed dietary supplement subset), the U.S. Patent 
and Trade Office (USPTO).  Additional American private or institution generated databases include HerbMedTM , the 
online Archive of American Folk Medicine and the Traditional Ecological Knowledge Prior Art Database (TEK*PAD) 
concerning indigenous knowledge and plant uses, which is  maintained by the American Association for the 
Advancement of Science.  
 Specialized for fee databases include in the U.S. Biosis Previews, which is considered the world’s largest 
database on medical and biological subjects with over 12 million citations. Access is available on line or through CD-
ROM distributors. In addition membership fees to the American Botanical Council are required to elicit 
HerbMedProTM,a more professional version of HerbMed® . This is an interactive herbal database developed by the 
Alternative Medicine Foundation linking scientific evidence underlying the use of herbs for health. Another fee based 
database is called MANTIS (Manual, Alternative and Natural Therapy Index), which utilizes ChiroACCESS;( the online 
Chiropractic community), Dialog Corporation, Health Index and OVID Technologies, Inc. Currently it cites about 
417,000 references obtained from over a thousand, mostly peer reviewed journals. 
 United Kingdom-based for fee databases include the CABI Medicinal Plant Database, which comprises 
aspects of human health and nutrition, the Hom-Inform Database produced by the British Homeoepathic Library at 
Glasgow Homoepathic Hospital and the Society of Homeopaths, Treuherz Collection, and the Index to Chiropractic 
Literature.  In France, the large multilingual bibliographic data base, PASCAL compiled by the Institute de 
l’Information Scientifique et Technique (INIST) can be accessed both online and offline and cites over 500,000 
records in science and technology.  
 Regional for fee or membership databases, may also be for sale in a CD- ROM format.  In Asia, these 
include the Korean and Chinese TradiMed, The Chinese TCM Database and Chinese Materia Medica, the Japanese 
JICSR-EPlus, and FRLHT (Bio-informatics on Medicinal Plants and Traditional Knowledge) based in India. The latter 
is a compilation of 7,500 botanical names associated with local traditional uses. The UNESCO-sponsored project, The 
Asian Pacific Information Network on Medicinal and Aromatic Plants (APINMAP) is a consortium of countries 
(Australia, People’s Republic of China, India, Indonesia, Republic of Korea, Malaysia, Nepal, Pakistan, Papua New 
guinea, the Philippines, Sri Lanka, Thailand, Turkey and Vietnam) with a Secretariat based in the Philippines.  Its 
database contains bibliographic and factual information on medicinal plants in addition to contact information and the 
activities of member scientists conducting research in this discipline.  Another Asian collaborative effort called the 
Asian Health, Environmental and Allied Databases (AHEAD) between India, Thailand, Philippines, Malaysia, 
Singapore and Bangladesh is sponsored by the International Development Research Center of Canada.  Coordinated 
in New Delhi by the National Institute of Science Communication (NISCOM) a 3 disc CD-ROM series has been 
developed on the Environment, Health and Wealth of Asia. Incorporated into the latter disc is the entire Medicinal and 
Aromatic Plants bibliographic database in addition to the plant and mineral resources listed in the Wealth of India.  
The African Health Anthology, produced by the National Information Services Corporation (NISC) South 
Africa, represents a compilation of comprehensive databases related to African health issues from 1924 to the 
present, including those related to alternative and complementary medicine.  Traditional Medicinal Plants of the 
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treasure.  In addition to the utilization from basic science databases, reference to those describing relevant clinical 
studies or patents is worthwhile.  
 Overall it is important to emphasize that it would be a rare event to identify from ethnobotanical sources 
potential pharmaceutical compounds, which are novel, potent and safe.  More than not, most plant remedies contain 
compounds that are moderate in efficacy and toxicity, and are too complex or ubiquitous to be categorized in this 
manner.  However, there are some plants or plant mixtures which merit consideration for use as botanicals or 
phytopharmaceuticals.  It is these approaches that are more likely to be pursued once basic studies have been 
completed in evaluating an indigenous pharmacopeia.  It is within this context that reference to known information is 
so very relevant and where benefit -sharing with those that are custodians of the original traditional knowledge are 
more likely to be achieved.  
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